Department of Cell Biology, Center for Cell Dynamics, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Department of Biomedicine, Cancer Metastasis Laboratory, University of Basel and University Hospital Basel, Basel, Switzerland.
Nature. 2019 Sep;573(7774):439-444. doi: 10.1038/s41586-019-1526-3. Epub 2019 Sep 4.
Metastasis is the major driver of death in patients with cancer. Invasion of surrounding tissues and metastasis have been proposed to initiate following loss of the intercellular adhesion protein, E-cadherin, on the basis of inverse correlations between in vitro migration and E-cadherin levels. However, this hypothesis is inconsistent with the observation that most breast cancers are invasive ductal carcinomas and express E-cadherin in primary tumours and metastases. To resolve this discrepancy, we tested the genetic requirement for E-cadherin in metastasis using mouse and human models of both luminal and basal invasive ductal carcinomas. Here we show that E-cadherin promotes metastasis in diverse models of invasive ductal carcinomas. While loss of E-cadherin increased invasion, it also reduced cancer cell proliferation and survival, circulating tumour cell number, seeding of cancer cells in distant organs and metastasis outgrowth. Transcriptionally, loss of E-cadherin was associated with upregulation of genes involved in transforming growth factor-β (TGFβ), reactive oxygen species and apoptosis signalling pathways. At the cellular level, disseminating E-cadherin-negative cells exhibited nuclear enrichment of SMAD2/3, oxidative stress and increased apoptosis. Colony formation of E-cadherin-negative cells was rescued by inhibition of TGFβ-receptor signalling, reactive oxygen accumulation or apoptosis. Our results reveal that E-cadherin acts as a survival factor in invasive ductal carcinomas during the detachment, systemic dissemination and seeding phases of metastasis by limiting reactive oxygen-mediated apoptosis. Identifying molecular strategies to inhibit E-cadherin-mediated survival in metastatic breast cancer cells may have potential as a therapeutic approach for breast cancer.
转移是癌症患者死亡的主要原因。基于体外迁移与 E-钙黏蛋白水平之间呈反比关系,人们提出,在细胞间黏附蛋白 E-钙黏蛋白丢失后,周围组织的侵袭和转移就会发生。然而,这一假说与以下观察结果不一致:大多数乳腺癌为浸润性导管癌,在原发性肿瘤和转移灶中均表达 E-钙黏蛋白。为了解决这一矛盾,我们利用人源和鼠源的腔面型和基底型浸润性导管癌模型,检测了 E-钙黏蛋白在转移中的遗传需求。研究结果表明,E-钙黏蛋白在多种浸润性导管癌模型中促进了转移。尽管 E-钙黏蛋白的丢失会增加侵袭性,但它也会降低癌细胞的增殖和存活率、循环肿瘤细胞的数量、肿瘤细胞在远处器官的定植和转移灶的生长。在转录水平上,E-钙黏蛋白的丢失与转化生长因子-β(TGFβ)、活性氧和细胞凋亡信号通路相关基因的上调有关。在细胞水平上,失去 E-钙黏蛋白的细胞表现出 SMAD2/3 的核内富集、氧化应激和凋亡增加。通过抑制 TGFβ 受体信号、活性氧积累或凋亡,E-钙黏蛋白阴性细胞的集落形成得到挽救。研究结果表明,E-钙黏蛋白在浸润性导管癌中作为一种生存因子发挥作用,通过限制活性氧介导的细胞凋亡,限制了转移过程中细胞的脱落、全身扩散和定植阶段。确定抑制转移性乳腺癌细胞中 E-钙黏蛋白介导的生存的分子策略,可能为乳腺癌的治疗提供新的方法。